Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in HER2-positive Metastatic Breast Cancer
NCT00431067Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2006
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of afatinib in breast cancer, sponsored by Boehringer Ingelheim. Primary endpoint: Objective Response at 34 months. Started Sep 2006; status: completed.
02
Drugs
afatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00431067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431067.